<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pain Res</journal-id><journal-id journal-id-type="iso-abbrev">J Pain Res</journal-id><journal-id journal-id-type="pmc-domain-id">1405</journal-id><journal-id journal-id-type="pmc-domain">jpainres</journal-id><journal-id journal-id-type="publisher-id">jpr</journal-id><journal-title-group><journal-title>Journal of Pain Research</journal-title></journal-title-group><issn pub-type="epub">1178-7090</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11162618</article-id><article-id pub-id-type="pmcid-ver">PMC11162618.1</article-id><article-id pub-id-type="pmcaid">11162618</article-id><article-id pub-id-type="pmcaiid">11162618</article-id><article-id pub-id-type="pmid">38854928</article-id><article-id pub-id-type="doi">10.2147/JPR.S457982</article-id><article-id pub-id-type="publisher-id">457982</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access</article-title><alt-title alt-title-type="running-authors">Webster and Gudin</alt-title><alt-title alt-title-type="running-title">Webster and Gudin</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8609-9424</contrib-id><name name-style="western"><surname>Webster</surname><given-names initials="L">Lynn</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gudin</surname><given-names initials="J">Jeffrey</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>Dr. Vince Clinical Research</institution>, <addr-line>Overland Park</addr-line>, <addr-line>KS</addr-line>, <country>USA</country></aff><aff id="aff0002"><label>2</label><institution>Department of Anesthesiology and Pain Management, University of Miami, Miller School of Medicine</institution>, <addr-line>Miami</addr-line>, <addr-line>FL</addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Lynn Webster, Dr. Vince Clinical Research, <addr-line>1285 3rd Avenue</addr-line>, <addr-line>Salt Lake City</addr-line>, <addr-line>UT</addr-line>, <addr-line>84103</addr-line>, <country>USA</country>, <phone content-type="general">Tel +1 801-560-1707</phone>, Email LRWebsterMD@gmail.com</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">452755</issue-id><fpage>1989</fpage><lpage>2000</lpage><history><date date-type="received"><day>17</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>09</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-10 17:25:26.090"><day>10</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Webster and Gudin.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Webster and Gudin.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v3.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jpr-17-1989.pdf"/><abstract><title>Abstract</title><p>The misuse and abuse of opioid analgesics continue to pose a serious public health concern, but for some patients, opioids remain an important analgesic option. Extended-release (ER) opioid formulations are effective for treating chronic pain and are supported by multiple 12-week efficacy studies. ER opioids often contain a high opioid content, and similar to immediate-release (IR) formulations, are subject to abuse, misuse, and diversion. Unintentional misuse may also occur when ER formulations are manipulated for medicinal administration, such as crushing a dose for easier oral intake. As part of a multipronged strategy designed to fight the opioid epidemic, abuse-deterrent formulations (ADFs) were developed to deter misuse, abuse, and diversion of opioids by making manipulation more difficult and nonoral routes of administration less rewarding. Although ADF opioids have been shown to decrease rates of abuse and diversion, they are not equally effective in terms of deterring manipulation for abuse or misuse. Xtampza ER utilizes DETERx technology, which allows it to retain ER characteristics when chewed or crushed, making it the only ER opioid without a boxed warning against these types of manipulation. OxyContin was also developed as an ADF but uses RESISTEC technology, making the tablet hard to crush and viscous in aqueous solutions. ADF utilization has been hampered by patient access issues, including high prices due to lack of insurance coverage. Postmarket real-world studies demonstrate lower rates of abuse, misuse, and diversion for ADF ER opioids compared with non-ADF formulations. However, similar studies comparing abuse-related effectiveness and health care costs for ADF opioids are warranted if clinicians are expected to utilize these potentially safer opioid formulations. These studies would support further education surrounding the benefits and utilization of ADFs and manipulation potential of different ADFs.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>opioid analgesics</kwd><kwd>opioid crisis</kwd><kwd>chronic pain</kwd><kwd>tamper</kwd><kwd>abuse-deterrent</kwd><kwd>extended release</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><ref-count count="84"/><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Pain and chronic pain (lasting &gt;3 months) are unpleasant sensory and emotional experiences associated with or resembling those associated with potential or actual tissue damage, which are highly debilitating and affect the quality of life of many adults in the US.<xref rid="cit0001" ref-type="bibr">1&#8211;3</xref> In 2021, an estimated 51.6 million adults in the US were affected by chronic pain and 17.1 million adults experienced high-impact chronic pain, defined as having pain every day or on most days during a 3-month period that substantially restricted participation in life or work activities.<xref rid="cit0002" ref-type="bibr">2</xref> Despite opioid misuse and abuse posing a serious and challenging public health problem, for a subset of patients with refractory pain, opioid analgesics remain an important component of pain management.<xref rid="cit0004" ref-type="bibr">4</xref> Common prescription opioids (limited to natural, semisynthetic, and methadone) were involved in 17,000 deaths (45 deaths per day) in the US in 2021.<xref rid="cit0005" ref-type="bibr">5</xref> Opioid use disorder (OUD) diagnoses and fatal overdoses increased dramatically during the COVID-19 pandemic.<xref rid="cit0006" ref-type="bibr">6</xref> A recent analysis by the Joint Economic Committee estimated that in 2020, the economic burden of illicit and licit opioid abuse and misuse reached almost $1.5 trillion.<xref rid="cit0007" ref-type="bibr">7</xref> A separate analysis considering the societal costs of OUD and opioid overdose deaths found that the greatest loss was the reduced quality of life from OUD and the value of life lost due to fatal opioid overdose.<xref rid="cit0008" ref-type="bibr">8</xref> These findings illustrate the magnitude of OUD as a persistent public health crisis and the devastating impact it has on individuals, families, and society.</p><p>Support for opioid treatment has come under scrutiny despite therapeutic benefit. Regulatory agencies including the US Food and Drug Administration (FDA) encourage the development of abuse-deterrent formulations (ADF) as part of a multipronged approach for combating opioid misuse and abuse while ensuring that appropriate patients are treated effectively. The aim of this review is to discuss the properties of the available ADF products with evidence for abuse deterrence (eg, physical and chemical barriers) and how these properties may reduce abuse potential. The barriers that limit access to effective opioid treatment are also discussed.</p></sec><sec id="s0002"><title>Pain Management and Risk of OUD</title><p>A trial of opioid therapy may be warranted if conservative and interventional analgesic treatments fail, and an individual&#8217;s risk for OUD should be taken into consideration before opioids are prescribed.<xref rid="cit0009" ref-type="bibr">9</xref> OUDs range from mild to severe and have been defined as possibly present &#8220;when a person craves or continues use and is unable to stop, even when physical, psychological, social, occupational, and other difficulties arise&#8221;.<xref rid="cit0009" ref-type="bibr">9</xref> OUD is not only a disease of exposure; rather, its etiology is multifaceted, involving psychosocial, genetic, and environmental factors.<xref rid="cit0010" ref-type="bibr">10</xref> Individuals at the highest risk for experiencing OUD may be genetically predisposed<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0012" ref-type="bibr">12</xref> and/or exposed to opioids at a vulnerable time (eg, while experiencing mental or physical distress or having a psychological disorder).<xref rid="cit0013" ref-type="bibr">13&#8211;16</xref> Other risk factors for OUD include a personal or family history of a substance use disorder, poor social support, preadolescent sexual abuse, stress due to uncontrolled pain, mental and emotional pain from histories of childhood or adult trauma, and/or nonfunctional status due to pain.<xref rid="cit0009" ref-type="bibr">9</xref> Geriatric patients have frequent comorbid medical conditions and age-related pain syndromes (eg, osteoarthritis) conferring specific risk factors for opioid-related harm because of polypharmacy; in addition, adverse effects related to opioid use, including sedation, risk of falls, and impaired cognitive functioning, need to be considered when initiating opioid treatment.<xref rid="cit0017" ref-type="bibr">17&#8211;19</xref> Certain other populations may be more vulnerable to OUD and adverse outcomes, including children and adolescents.<xref rid="cit0020" ref-type="bibr">20</xref> Key risk factors for opioid misuse in adolescents and young adults are prescription opioid use and age at exposure.<xref rid="cit0020" ref-type="bibr">20</xref>,<xref rid="cit0021" ref-type="bibr">21</xref> However, acute exposure alone is usually insufficient for severe OUD to occur. For example, a long duration of first opioid treatment and administration of long-acting opioids have the potential to increase the risk of opioid misuse in young individuals.<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref> Therefore, the benefits of initiating opioid therapy must outweigh the risks of opioid addiction, abuse, and misuse in all patients, but particularly in more vulnerable and special-risk populations.</p><p>The abuse potential of an opioid is influenced by pharmacologic factors including route of administration, rate of administration, and absorption rate.<xref rid="cit0024" ref-type="bibr">24</xref> Drug manipulation (eg, crushing, injecting, or snorting) achieves a fast rate of drug onset,<xref rid="cit0025" ref-type="bibr">25</xref> and rapid administration of opioids results in higher plasma levels, increased drug effect, and greater drug liking.<xref rid="cit0024" ref-type="bibr">24</xref> Immediate-release (IR) opioids generally provide a faster absorption rate, resulting in greater drug exposure when doses are equivalent, and may lead to greater drug liking when compared to intact extended-release (ER) formulations.<xref rid="cit0024" ref-type="bibr">24</xref> ER opioids are designed to provide an extended period of analgesia with less frequent dosing compared to IR formulations.<xref rid="cit0026" ref-type="bibr">26</xref> This is achieved by a controlled release of the active agent to provide consistent and prolonged plasma drug levels.<xref rid="cit0025" ref-type="bibr">25</xref> Furthermore, the time to peak blood concentration level (T<sub>max</sub>) is generally longer with ER formulations, reducing abuse liabilities when taking whole tablets as intended.</p><p>ER opioid analgesics are indicated for the treatment of severe and persistent pain that requires an extended treatment period for which alternative pain management options are inadequate.<xref rid="cit0026" ref-type="bibr">26&#8211;29</xref> ER opioids have shown safety and efficacy in clinical trials for the control of various chronic pain conditions.<xref rid="cit0030" ref-type="bibr">30&#8211;33</xref> However, ER formulations typically have higher levels of active drugs that are appealing for nonmedical use and abuse and are therefore susceptible to abuse through tampering or swallowing multiple tablets.<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0026" ref-type="bibr">26</xref> The Research Abuse, Diversion and Addiction-Related Surveillance (RADARS) system found that prescription-adjusted rates of abuse and diversion (defined as an instance of unlawful channeling of a product of interest from legal sources that results in a written report or complaint) for ER opioids were 2.8-fold and 2.1-fold higher, respectively, than IR opioids.<xref rid="cit0034" ref-type="bibr">34</xref> This may be due to high-risk patients preferring to abuse ER medication.<xref rid="cit0034" ref-type="bibr">34</xref> On the other hand, prescription opioid abuse and diversion are declining more rapidly for ER than for IR opioid medications.<xref rid="cit0034" ref-type="bibr">34</xref> The American Academy of Pain Medicine Board of Directors has endorsed 8 key principles for safer opioid prescribing, including risk assessment of patients for opioid misuse prior to initiating opioid therapy and monitoring of patients during therapy as well as avoidance of long-acting opioid formulations for acute, postoperative, or trauma-related pain.<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0036" ref-type="bibr">36</xref> Moreover, the Department of Veterans Affairs and Department of Defense practice guidelines also recommend against the use of long-acting opioids on initiation of opioid therapy, and IR opioids should be prescribed at the lowest effective dose for acute pain.<xref rid="cit0037" ref-type="bibr">37</xref></p></sec><sec id="s0003"><title>Role of Abuse Deterrent Formulations in Reducing Abuse and Misuse</title><p>Three key characteristics of opioid medications that have been found to influence the risk of harms are the chemical compound, the formulation, and the intended route of administration.<xref rid="cit0038" ref-type="bibr">38</xref> ADFs were developed as a component of a multifactorial strategy to combat the opioid epidemic by addressing these characteristics via modification of the opioid formulation to prevent unintended routes of administration. ADFs may hinder manipulation or make the tampered formulation less rewarding, reducing drug liking and, potentially, diversion. In support of their intended abuse-deterrent functions, the introduction of ADF analgesics has been associated with decreased rates of diversion and abuse.<xref rid="cit0039" ref-type="bibr">39</xref> This finding indicates that ADFs have the potential to substantially reduce the incidence of opioid abuse relative to non-ADFs, although ADFs can still be abused and misused, mostly through oral overconsumption.<xref rid="cit0040" ref-type="bibr">40</xref>,<xref rid="cit0041" ref-type="bibr">41</xref></p><p>The FDA outlines 4 categories (<xref rid="t0001" ref-type="table">Table 1</xref>) of research to evaluate abuse deterrence, including 3 types of premarket studies (Categories 1&#8211;3) and 1 postmarket study (Category 4):<xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0043" ref-type="bibr">43</xref> Category 1 consists of in vitro manipulation and extraction studies to evaluate the ease with which the potential abuse-deterrent properties can be defeated or compromised; Category 2 includes pharmacokinetic (PK) studies to understand in vivo properties of the formulation by comparing the PK profile of the manipulated formulation with the intact formulation and with manipulated and intact formulations of comparator drugs; Category 3 involves human abuse-potential studies to evaluate the impact of potentially abuse-deterrent properties by assessing drug liking, willingness to take drug again, and other abuse-related measures in recreational users; and Category 4 incorporates data from postmarket epidemiologic studies to determine the real-world impact on abuse, misuse, and other adverse clinical outcomes.<xref rid="cit0042" ref-type="bibr">42</xref>,<xref rid="cit0043" ref-type="bibr">43</xref> Currently, no ADF has been labeled as Category 4 by the FDA, underscoring the need for more postmarketing assessments of the real-world abuse-deterrent effects of currently available ADFs.
<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>US Food and Drug Administration&#8211;Recommended Studies of Abuse Deterrent Technologies</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Category 1</th><th rowspan="1" colspan="1">Category 2</th><th rowspan="1" colspan="1">Category 3</th><th rowspan="1" colspan="1">Category 4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Type of study</td><td rowspan="1" colspan="1">Laboratory-based in vitro manipulation and extraction studies</td><td rowspan="1" colspan="1">PK studies</td><td rowspan="1" colspan="1">Clinical abuse potential studies</td><td rowspan="1" colspan="1">Postmarket studies</td></tr><tr><td rowspan="1" colspan="1">Objective</td><td rowspan="1" colspan="1">To evaluate the ease of defeating or compromising abuse-deterrent properties of the formulation</td><td rowspan="1" colspan="1">To determine in vivo properties of the formulation by comparing the PK profiles of the manipulated vs intact formulations and with comparator drugs through 1 or more routes of administration</td><td rowspan="1" colspan="1">To assess the abuse potential of the formulation, preferably in a randomized, double-blind, placebo-controlled trial with a drug-experienced, recreational user population</td><td rowspan="1" colspan="1">To demonstrate meaningful reductions in abuse, misuse, and related adverse clinical outcomes including addiction, overdose, and death in postapproval settings</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Abbreviation</bold>: PK, pharmacokinetic.</p></fn></table-wrap-foot></table-wrap></p><p>To date, there are 4 opioids (1 IR and 3 ER) with FDA-approved abuse-deterrence label claims&#8212;Roxybond IR (oxycodone hydrochloride), reformulated OxyContin (oxycodone hydrochloride), Hysingla ER (hydrocodone bitartrate), and Xtampza ER (oxycodone)&#8212;each designed with mechanisms to deter abuse and potentially avoid intentional misuse (<xref rid="t0002" ref-type="table">Table 2</xref>).<xref rid="cit0043" ref-type="bibr">43</xref>
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Evidence of Abuse Deterrence for Currently Available ADFs</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">ADF</th><th rowspan="1" colspan="1">Manufacturer</th><th rowspan="1" colspan="1">Active Compound</th><th rowspan="1" colspan="1">Year of Approval</th><th rowspan="1" colspan="1">Mechanism of Deterrence</th><th rowspan="1" colspan="1">Deterred Routes of Abuse</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">OxyContin</td><td rowspan="1" colspan="1">Purdue Pharma LP</td><td rowspan="1" colspan="1">Oxycodone</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">Intac technology employs a matrix drug delivery system that controls the rate of release of the active ingredient<xref rid="cit0044" ref-type="bibr">44</xref><break/>RESISTEC employs a combination of polymer and processing that confers tablet hardness, imparts viscosity when dissolved in aqueous solutions, and resists drug release rate when mixed with alcohol<xref rid="cit0045" ref-type="bibr">45</xref></td><td rowspan="1" colspan="1">Injection: becomes viscous in liquid<break/>Intranasal: tablets are difficult to crush</td></tr><tr><td rowspan="1" colspan="1">Hysingla ER</td><td rowspan="1" colspan="1">Purdue Pharma LP</td><td rowspan="1" colspan="1">Hydrocodone bitartrate</td><td rowspan="1" colspan="1">2015</td><td rowspan="1" colspan="1">RESISTEC employs a combination of polymer and processing that confers tablet hardness and imparts viscosity when dissolved in aqueous solutions<xref rid="cit0046" ref-type="bibr">46</xref></td><td rowspan="1" colspan="1">Injection: becomes viscous in liquid<break/>Intranasal: tablets are difficult to crush</td></tr><tr><td rowspan="1" colspan="1">Roxybond IR</td><td rowspan="1" colspan="1">Protega Pharmaceuticals LLC</td><td rowspan="1" colspan="1">Oxycodone</td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">SentryBond combines inactive ingredients with the active opioid to slow the IR properties when manipulated<xref rid="cit0047" ref-type="bibr">47</xref></td><td rowspan="1" colspan="1">Injection: becomes viscous in liquid<break/>Intranasal: slow and low absorption</td></tr><tr><td rowspan="1" colspan="1">Xtampza ER</td><td rowspan="1" colspan="1">Collegium Pharmaceutical, Inc</td><td rowspan="1" colspan="1">Oxycodone</td><td rowspan="1" colspan="1">2016</td><td rowspan="1" colspan="1">DETERx employs hydrophobic, waxy microspheres, which have ER properties that are resistant to manipulation, including cutting, crushing, grinding, chewing, dissolving in solutions (becomes viscous in liquid), injecting after crushing, melting, or extracting<xref rid="cit0048" ref-type="bibr">48</xref></td><td rowspan="1" colspan="1">Injection: becomes viscous in liquid<break/>Oral: retains ER properties when crushed or chewed<break/>Intranasal: retains ER properties when crushed and snorted</td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p><bold>Abbreviations</bold>: ADF, abuse-deterrent formulation; ER, extended-release; IR, immediate-release.</p></fn></table-wrap-foot></table-wrap></p><p>Roxybond is the only abuse-deterrent IR opioid formulation currently available. Roxybond includes inactive ingredients that make the tablets harder to tamper with by physical manipulation and chemical extraction for intranasal or intravenous (IV) abuse.<xref rid="cit0049" ref-type="bibr">49</xref> OxyContin (oxycodone controlled-release) was first approved by the FDA in 1995. It was subsequently reformulated to include abuse-deterrent properties, and the ADF version was approved in 2010 under the same name.<xref rid="cit0050" ref-type="bibr">50</xref>,<xref rid="cit0051" ref-type="bibr">51</xref> The current formulation of OxyContin uses physical and chemical properties that make it more difficult to crush the tablet and make it resistant to ethanol and other chemical-extraction techniques that enhance dose dumping.<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0052" ref-type="bibr">52</xref> The reformulated OxyContin is designed to prevent manipulation for intranasal and IV administration but can be manipulated for oral use.<xref rid="cit0049" ref-type="bibr">49</xref> Similar to OxyContin, Hysingla ER is formulated with physical and chemical properties that render it difficult to crush, break, or dissolve and are expected to deter intranasal and IV abuse and oral abuse when chewed.<xref rid="cit0049" ref-type="bibr">49</xref></p><p>Xtampza ER differs from the other 3 ADF opioids; it is an ER opioid formulation that utilizes DETERx technology, a microsphere-in-capsule formulation with each individual microsphere acting as its own drug delivery system to maintain its ER PK profile even after chewing and crushing.<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0053" ref-type="bibr">53</xref> Xtampza ER is relatively resistant to crushing because of 3 unique physicochemical characteristics. First, the waxy nature of the formulation can cause microspheres to smear instead of breaking into small particles, which could reduce drug release.<xref rid="cit0054" ref-type="bibr">54</xref> Second, the hydrophobic nature of Xtampza ER formulation and the uniform composition of microspheres that distribute the active pharmaceutical ingredients (API) evenly limit the rate of extraction of the API.<xref rid="cit0054" ref-type="bibr">54</xref> Finally, the median particle size of the microspheres is approximately 300 &#181;m, and the changes to the surface area caused by crushing are inconsequential.<xref rid="cit0054" ref-type="bibr">54</xref> When crushed and heated for intended IV use, Xtampza ER will become viscous and difficult and perhaps dangerous to inject.<xref rid="cit0048" ref-type="bibr">48</xref> Therefore, it is neither cost- nor time-effective and is potentially dangerous to attempt oxycodone extraction from Xtampza ER.<xref rid="cit0048" ref-type="bibr">48</xref> Xtampza ER was designed to have significantly lower abuse potential compared to IR oxycodone via the oral route.<xref rid="cit0055" ref-type="bibr">55</xref> Xtampza ER&#8217;s purported lower abuse potential is partially due to its slower T<sub>max</sub> than, for example, oral administration of crushed oxycodone IR or crushed OxyContin (<xref rid="f0001" ref-type="fig">Figure 1</xref>).<xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>The mean plasma oxycodone concentration over time following oral administration of Xtampza ER (intact and crushed; left panel), OxyContin (intact and crushed; right panel), and crushed oxycodone IR. In an open-label, randomized, active-controlled, 5-treatment, 5-period, naltrexone-blocked crossover comparison study, blood samples were collected from healthy participants to compare the pharmacokinetics profile of Xtampza ER with OxyContin. IR oxycodone crushed, n=38; Xtampza ER intact, n=38; Xtampza crushed ER, n=40; Oxycontin intact, n=39; OxyContin crushed, n=39. Used with permission of Future Medicine Ltd, from Brennan MJ, Kopecky EA, Marseilles A, O&#8217;Connor M, Fleming AB. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza&#174; ER compared with OxyContin&#174;. <italic toggle="yes">Pain Manag</italic>. 2017;7(6):461&#8211;472; permission conveyed through Copyright Clearance Center, Inc.<xref rid="cit0056" ref-type="bibr">56</xref></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JPR-17-1989-g0001.jpg"/></fig></p><p>All 3 ER ADFs include abuse-deterrence claims in section 9.2 in the product labeling with supporting results from Category 1 and 3 studies; Xtampza ER also has data supporting Category 2 evaluation.<xref rid="cit0042" ref-type="bibr">42</xref> In vitro (Category 1) studies demonstrated that Hysingla has physical and chemical properties expected to deter intranasal and IV abuse, while OxyContin and Xtampza ER have physiochemical properties expected to make abuse via injection difficult.<xref rid="cit0042" ref-type="bibr">42</xref> Human abuse potential (Category 3) studies showed that Hysingla is expected to reduce intranasal abuse and oral abuse when chewed, while OxyContin is expected to reduce abuse by the intranasal route and Xtampza ER is expected to reduce abuse via the oral and intranasal routes.<xref rid="cit0042" ref-type="bibr">42</xref> Data from in vivo PK (Category 2) studies in Xtampza ER indicate a lack of dose dumping, with no increase in oxycodone levels when crushed or chewed compared with intact Xtampza ER.<xref rid="cit0042" ref-type="bibr">42</xref></p></sec><sec id="s0004"><title>Manipulation Methods</title><p>Abuse, misuse, and diversion of opioids, including ADF opioids, remain a public health problem. ADFs do not alter the addictive properties of the opioid molecule itself, and while ADFs may deter abuse, they are not resistant to all abuse. For example, current ADF technologies do not deter swallowing several intact capsules or tablets to achieve a feeling of a desired drug effect like euphoria. For this reason, ADFs still carry a risk of overdose (<xref rid="t0003" ref-type="table">Table 3</xref>).
<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3</label><caption><p>Impact of ADF on Abuse and Misuse Behaviors in Individuals Seeking or Entering Opioid Treatment Programs</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Publications</th><th rowspan="1" colspan="1">Key Findings</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cicero TJ et al. <italic toggle="yes">JAMA Psychiatry</italic>. 2015<xref rid="cit0057" ref-type="bibr">57</xref></td><td rowspan="1" colspan="1">Abusers who used both pre-ADF and reformulated OxyContin were able to successfully overcome the ADF mechanism and effectively manipulate the reformulated OxyContin for use via IV and inhalation routes.</td></tr><tr><td rowspan="1" colspan="1">Butler SF et al. <italic toggle="yes">Pain Med</italic>. 2018<xref rid="cit0058" ref-type="bibr">58</xref></td><td rowspan="1" colspan="1">Although the reformulated OxyContin was designed as a crush-resistant tablet (ADF mechanism), individuals who orally abused opioids reported being able to manipulate the crush-resistant tablets (eg, chewing or dissolving) before oral ingestion.</td></tr><tr><td rowspan="1" colspan="1">Green JL et al. <italic toggle="yes">J Pain Res</italic>. 2021<xref rid="cit0059" ref-type="bibr">59</xref></td><td rowspan="1" colspan="1">Rates of nonmedical use (deviation from legitimate medical use) of Xtampza ER were lower than other oxycodone ER (eg, OxyContin) and IR products.</td></tr><tr><td rowspan="1" colspan="1">Severtson SG et al. <italic toggle="yes">Pain Med</italic>. 2020<xref rid="cit0060" ref-type="bibr">60</xref></td><td rowspan="1" colspan="1">Rates of abuse, misuse, and diversion were lower for Xtampza ER compared with other ADF ER opioids (eg, Oxycontin), non-ADF ER opioids (eg, nonbranded ER morphine), and IR oxycodone.</td></tr><tr><td rowspan="1" colspan="1">Jewell J et al. <italic toggle="yes">Clin Drug Investigation</italic>. 2023<xref rid="cit0061" ref-type="bibr">61</xref></td><td rowspan="1" colspan="1">The odds of tampering (oral and nonoral) with an ADF opioid (eg, Xtampza ER and OxyContin) were reduced at least 70% compared with other non-ADF opioids.</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Abbreviations</bold>: ADF, abuse-deterrent formulation; ER, extended-release; IR, immediate-release; IV, intravenous.</p></fn></table-wrap-foot></table-wrap></p><p>The current prevailing ADF technology and most frequently prescribed is the reformulated hard-to-crush tablet OxyContin. A recent analysis of data from the RADARS system found that severe life-threatening events and death are twice as likely to occur with intentional abuse of prescription opioids when taken via nonoral routes of administration compared to oral routes.<xref rid="cit0062" ref-type="bibr">62</xref> One study showed that 34% of abusers (N=88) successfully overcame the ADF mechanism and effectively manipulated OxyContin for use via IV and inhalation routes.<xref rid="cit0057" ref-type="bibr">57</xref> Moreover, abuse of OxyContin occurs orally. For example, a real-world analysis of individuals seeking substance abuse treatment (N=18,135) found that up to 42% of oral abusers of crush-resistant tablets reported manipulating the pill (eg, chewing or dissolving).<xref rid="cit0058" ref-type="bibr">58</xref> In a separate study of OxyContin abusers (N=1705), up to 76% reported oral abuse of OxyContin (<xref rid="f0002" ref-type="fig">Figure 2</xref>).<xref rid="cit0063" ref-type="bibr">63</xref>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>OxyContin abusers and their route of administration. A sentinel surveillance sample of 140,496 individuals assessed for substance abuse treatment at 357 US centers between June 1, 2009, and March 31, 2012, was examined. Data on the route of administration used (percent) by OxyContin abusers (N=1705) after the introduction of reformulated OxyContin are shown. Adapted from <italic toggle="yes">J Pain</italic>, volume 14(4), Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. 351&#8211;358, Copyright 2013, with permission from Elsevier.<xref rid="cit0063" ref-type="bibr">63</xref></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="JPR-17-1989-g0002.jpg"/></fig></p><p>OxyContin is problematic for patients with chronic pain who also have dysphagia or odynophagia and who must crush or break tablets to ingest their medication or have it administered via an enteral tube.<xref rid="cit0064" ref-type="bibr">64</xref> Xtampza ER is the only form of oxycodone that can be taken by sprinkling the capsule contents on soft foods or into a cup and then administering directly into the mouth or through a gastrostomy or nasogastric feeding tube. In addition to being less attractive to illicit drug users, this formulation provides a viable option for patients who require such crushing or dissolving of their medication (due to difficulty swallowing).<xref rid="cit0064" ref-type="bibr">64</xref> A randomized, double-blind, placebo-controlled study showed that both chewed and intact Xtampza ER were bioequivalent, whereas crushed oxycodone IR yielded higher peak plasma concentrations (C<sub>max</sub>) compared with similar Xtampza ER doses using any method of administration.<xref rid="cit0065" ref-type="bibr">65</xref> Crushed oxycodone IR had an approximately 10-fold higher abuse quotient score (estimation of the relative abuse potential of different formulations based on a ratio of C<sub>max</sub> to T<sub>max</sub>) compared with both chewed and intact Xtampza ER.<xref rid="cit0065" ref-type="bibr">65</xref> The T<sub>max</sub> was significantly longer for intact or chewed Xtampza ER (~3&#8211;5 hours) than for crushed IR oxycodone (1 hour).<xref rid="cit0065" ref-type="bibr">65</xref> If the time to onset is attractive to misusers, these findings would suggest that Xtampza ER should have less appeal to individuals seeking a more rapid drug effect.</p><p>Real-world evidence (RWE) provides supporting information on the relative risk of abuse of currently available opioid medications. An analysis of the Addiction Severity Index-Multimedia Version found that Xtampza ER had significantly lower rates of nonmedical use and nonoral nonmedical use than OxyContin and non-ADF oxycodone IR products in individuals seeking substance abuse treatment.<xref rid="cit0059" ref-type="bibr">59</xref> A study evaluating the RADARS system found low rates of abuse/misuse (composite endpoint of cases by combining 3 exposure categories: intentional abuse, intentional misuse, and intentional unknown exposures as defined in the annual report of the National Poison Data System) and diversion of Xtampza ER compared with other prescription opioid analgesics.<xref rid="cit0060" ref-type="bibr">60</xref> Moreover, abuse and misuse did not increase for 3 years (July 1, 2016, through June 30, 2019) after initial marketing of Xtampza ER into the US market.<xref rid="cit0060" ref-type="bibr">60</xref> A recent postmarketing study found that Xtampza ER demonstrated reduced odds of tampering compared to non-ADF oxycodone IR and ER oxymorphone in a treatment-center population; no differences in tampering were observed between Xtampza ER and other ER oxycodone ADF opioids.<xref rid="cit0061" ref-type="bibr">61</xref> After the introduction of reformulated OxyContin in 2010, the rate of doctor-shopping for OxyContin declined by 50% over 3 years, which is the practice of obtaining multiple prescriptions from visiting multiple physicians. The decline was less for other prescription opioid comparators (eg, IR hydromorphone), ranging only from 9% to 25%, while an increase was observed for ER oxymorphone (66%). These findings suggest that ADF opioids reduce doctor-shopping, which is associated with high risks for abuse and diversion due to the amount of excess drugs procured.<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0067" ref-type="bibr">67</xref> In the same 3-year period, diversion events for OxyContin decreased by 66%, as reported by law enforcement officials in the RADARS drug diversion study.<xref rid="cit0067" ref-type="bibr">67</xref> In a postmarketing analysis, rates of diversion were found to be 4.1-fold higher for other ADF ER opioids (eg, Oxycontin), 3.7-fold higher for IR oxycodone, and 3.4-fold higher for non-ADF ER opioids compared with Xtampza ER over 3 years.<xref rid="cit0060" ref-type="bibr">60</xref> Taken together, these RWE studies suggest that drugs employing ADF technology, specifically Xtampza ER, reduce the likelihood of abuse, misuse, and diversion when compared with non-ADF prescription analgesics.</p><p>Since the early 2010s, the amount of opioids prescribed and dispensed has decreased, which corresponds to the introduction of ADF opioids, including the reformulated OxyContin and Xtampza ER.<xref rid="cit0068" ref-type="bibr">68&#8211;71</xref> A recent analysis using a large nationally representative prescription database found a 32% decrease in the total number of opioid analgesic prescriptions between 2016 and 2021.<xref rid="cit0070" ref-type="bibr">70</xref> This decrease in the amount of opioids prescribed and dispensed may be attributed to several reasons, including strict regulations for opioid distribution<xref rid="cit0072" ref-type="bibr">72</xref> and cautious opioid prescribing practices.<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0073" ref-type="bibr">73</xref></p></sec><sec id="s0005"><title>Prescriber and Insurance Perspective</title><p>Health care providers are generally aware of oxycodone&#8217;s efficacy, but there appears to be little insight into the potential for manipulation with different oxycodone formulations (<xref rid="t0004" ref-type="table">Table 4</xref>). A survey of licensed physicians found that &gt;50% believe that all ADFs are equally effective in preventing abuse and misuse by various routes of internalization (eg, intact oral vs crushing/grinding) despite explicit labeling, while about a third of physicians were unsure.<xref rid="cit0074" ref-type="bibr">74</xref> These findings indicate a need for improved prescriber education, beyond product labels, regarding the abuse-deterrent mechanisms for different ADFs.<xref rid="cit0074" ref-type="bibr">74</xref> Patient education by practitioners needs to include information on the risks of opioid abuse and diversion, appropriate use of opioid formulations, and proper medication storage and disposal.<xref rid="cit0049" ref-type="bibr">49</xref> Effective patient education can only be possible when prescribers are well educated in pain management and safe opioid usage. To ensure that the benefits of opioid formulations outweigh the risk of addiction, abuse, and misuse, the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for opioid products.<xref rid="cit0075" ref-type="bibr">75</xref> For this reason, the FDA recommends that all health care practitioners involved in the management of pain in patients should be educated about the fundamentals of acute and chronic pain management, including the risks and safe use of opioids and the prevention, diagnosis, and management of OUD.<xref rid="cit0075" ref-type="bibr">75</xref>
<table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4</label><caption><p>Barriers to Opioid Treatment Access</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Publications</th><th rowspan="1" colspan="1">Key Findings</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Dasgupta N et al. <italic toggle="yes">Pain Ther</italic>. 2022<xref rid="cit0074" ref-type="bibr">74</xref></td><td rowspan="1" colspan="1">Provider barriers: Many clinicians have insufficient training and education regarding the potential efficacy of ADFs in preventing abuse and misuse despite explicit labeling.</td></tr><tr><td rowspan="1" colspan="1">Brooks A and Kominek C. <italic toggle="yes">Pain Med</italic>. 2018;<xref rid="cit0076" ref-type="bibr">76</xref> Petrilla A et al. <italic toggle="yes">Am Health Drug Benefits</italic>. 2020;<xref rid="cit0077" ref-type="bibr">77</xref> Kumar VM et al. <italic toggle="yes">Value Health</italic>. 2019<xref rid="cit0078" ref-type="bibr">78</xref></td><td rowspan="1" colspan="1">Financial barriers: High costs and lack of insurance coverage for ADF opioids exclude access for many patients. Financial burden to the health care system was found to be greater in a cost-effectiveness model, mostly due to higher ADF opioid drug costs.</td></tr><tr><td rowspan="1" colspan="1">Gill S et al. <italic toggle="yes">BJGP Open</italic>. 2022<xref rid="cit0079" ref-type="bibr">79</xref></td><td rowspan="1" colspan="1">Institutional barriers: Fragmented care for pain management, including lack of continuity of care and resources for pain management support for difficult-to-treat patients, impede effective prescribing practices by physicians.</td></tr><tr><td rowspan="1" colspan="1">Litman RS et al. <italic toggle="yes">Anesthesiology</italic>. 2018<xref rid="cit0080" ref-type="bibr">80</xref></td><td rowspan="1" colspan="1">Regulatory barriers: Although some states have approved legislation mandating insurance coverage and availability of ADFs on formularies, the legislation is not introduced or approved in a majority of states.</td></tr></tbody></table><table-wrap-foot><fn id="tfn0004"><p><bold>Abbreviation</bold>: ADF, abuse-deterrent formulation.</p></fn></table-wrap-foot></table-wrap></p><p>In order to continue to improve outcomes and define the standard of care associated with the use of opioid analgesics, regulatory policy and medical guidelines need to be evidence-based. Understanding the factors that influence prescribing IR vs ER or ADFs over non-ADF opioid formulations is critical. In a survey evaluating physician beliefs, behaviors, and psychology, one-third (n=130) of 374 physicians considered whether an opioid had tamper-deterring properties when prescribing.<xref rid="cit0074" ref-type="bibr">74</xref> Their motivation for prescribing ADFs was largely influenced by potential patient/family diversion and reducing the societal supply and less related to patient-level abuse concerns.<xref rid="cit0074" ref-type="bibr">74</xref> A lack of ADF opioid utilization by prescribers may be influenced by selective prescribing and the bias that opioid abuse is a family and societal issue rather than a patient abuse and misuse issue. In support of this theory, this survey also found that only 57% of prescribers agreed that opioid abuse was a problem in their practice, while emergency department physicians were more likely to acknowledge opioid abuse as a problem among their patients.<xref rid="cit0074" ref-type="bibr">74</xref> Lack of continuity of care and pain management support resources, especially for chronic pain patients, contribute to fragmented care for pain management and hinder optimal prescribing practices.<xref rid="cit0079" ref-type="bibr">79</xref></p><p>ADF opioid analgesics are currently only available as branded drugs and are therefore significantly more expensive than non-ADF opioid analgesics. Moreover, ADFs generally have higher costs than IR formulations and non-ADFs due to the added cost of manufacturing the advanced technology.<xref rid="cit0076" ref-type="bibr">76</xref> The Institute of Clinical and Economic Review performed a cost-effectiveness model and estimated that 2300 new cases of abuse may be prevented with ADF opioids compared with 6600 abuse-years that may be associated with non-ADF opioids over a 5-year time period; however, the financial burden to the health care system (approximately $525 million) was greater, mostly due to higher ADF opioid drug costs.<xref rid="cit0078" ref-type="bibr">78</xref> To achieve cost-neutrality (ie, $0 cost to the health care system) between ADFs and non-ADFs, the relative risk of diversion in the ADF cohort would need to decrease by approximately 43%.<xref rid="cit0078" ref-type="bibr">78</xref> A recent US retrospective claims analysis comparing health care costs of patients transitioning from an IR opioid to either Xtampza ER or OxyContin found that outpatient ER opioid costs were lower for Xtampza ER compared to OxyContin during a 9-month follow-up ($2645 vs $3141, <italic toggle="yes">p</italic>&lt;0.001),<xref rid="cit0081" ref-type="bibr">81</xref> although this could be influenced by the payer. Nevertheless, further studies on postmarket real-world data comparing abuse-related effectiveness and health care costs associated with ADF opioids and non-ADF counterparts are warranted.<xref rid="cit0078" ref-type="bibr">78</xref></p><p>Cost is a significant barrier for patients not receiving an opioid ADF. In fact, cost was found to be one of the most common motivating factors for not prescribing ADFs. Among physicians who prescribed ADFs, 25.4% recalled a patient asking for a non-ADF, putatively because of cost. In the same survey, 64% of prescribers were concerned about third-party payer costs. When contacted by a pharmacist to switch an ADF-containing opioid to a non&#8211;ADF-containing opioid due to cost, prescribers reported capitulating in nearly every instance, but these instances were reported by a low percentage (3.8%) of surveyed prescribers.<xref rid="cit0074" ref-type="bibr">74</xref> Adding to cost-hindrance, access to ADFs may be limited by inadequate insurance coverage and prior authorization requirements.<xref rid="cit0076" ref-type="bibr">76</xref> To reduce or eliminate barriers to ADF access, several companies that produce ADF opioids include on their websites information about cost-saving programs and tools for determining payer coverage.<xref rid="cit0076" ref-type="bibr">76</xref> As of January 2022, 38 states had implemented policies and/or guidelines setting opioid supply limits or requiring that doctors prescribe the lowest effective dose.<xref rid="cit0082" ref-type="bibr">82</xref></p><p>Broad formulary coverage for ADF opioids has been associated with decreased rates of opioid abuse and overdose in real-world managed care populations.<xref rid="cit0077" ref-type="bibr">77</xref> Some states have introduced legislation mandating insurance coverage and availability of ADF opioids on formularies.<xref rid="cit0049" ref-type="bibr">49</xref> Several states have also introduced legislation mandating automatic replacement of non-ADF opioids with an ADF counterpart at no additional cost to the patient.<xref rid="cit0076" ref-type="bibr">76</xref>,<xref rid="cit0080" ref-type="bibr">80</xref> As of April 2017, this type of legislation had passed in 5 states (West Virginia, Florida, Maryland, Maine, and Massachusetts) and had been introduced in 10 more states.<xref rid="cit0080" ref-type="bibr">80</xref></p></sec><sec id="s0006"><title>Conclusions</title><p>Prescription opioid abuse may be stabilizing or decreasing due to a variety of factors, including reductions in opioid prescribing and dispensing rates; introduction of ADFs; and local, state, and federal programs to improve opioid prescribing practices.<xref rid="cit0057" ref-type="bibr">57</xref>,<xref rid="cit0083" ref-type="bibr">83</xref>,<xref rid="cit0084" ref-type="bibr">84</xref> ADFs, such as Xtampza ER and OxyContin, were designed as part of a multifactorial strategy to address the opioid epidemic; however, not all ADFs are equivalent in their ability to deter opioid diversion and manipulation. Xtampza ER is formulated to provide prolonged pain relief with a controlled release of the active agent to provide consistent and prolonged plasma drug levels. Xtampza ER requires less frequent dosing, leading to fewer pills compared with IR opioids, and offers multiple dosing options. The DETERx technology maintains Xtampza&#8217;s ER PK profile even after chewing or crushing, making it difficult to manipulate Xtampza ER for IV or oral abuse. Cost is an important barrier to patients accessing ADF opioids, although the economic (eg, increased health care, criminal justice, and lost productivity) and societal (eg, lost health-related quality of life, death, substantially reduced quality of life for friends and family for a loved one with OUD) costs of OUD are high. Health care providers need increased awareness and education on opioids in general, the benefits of ADFs, manipulation potential of different ADFs, and guidance on how to educate their patients to safely store and dispose of prescription opioids.</p></sec></body><back><ack><title>Acknowledgments</title><p>This review was funded by Collegium Pharmaceutical, Inc. Technical and editorial support for this manuscript was provided by MedLogix Communications, LLC, and funded by Collegium Pharmaceutical, Inc.</p></ack><sec id="s0007"><title>Author Contributions</title><p>All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors were involved in writing and reviewing the manuscript.</p></sec><sec sec-type="COI-statement" id="s0008"><title>Disclosure</title><p>LW is a consultant for CognifiSense, Collegium, Elysium Pharmaceuticals, Ensysce Biosciences, Quivive Pharma, Salix Pharmaceuticals, Trevi Therapeutics; advisory board of AdhereRx, Ensysce Biosciences, KemPharm, MedLogix; travel expenses from AdhereRx, Elysium Pharmaceuticals, Ensysce Biosciences, PainScript. JG is a consultant for Collegium, Hisamitsu, Kailo, Protega, Quest Diagnostics, Sanofi; shareholder for Virpax. The authors report no other conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Raja</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Carr</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>M</given-names></string-name>, et al. <article-title>The revised international association for the study of pain definition of pain: concepts, challenges, and compromises</article-title>. <source><italic toggle="yes">Pain</italic></source>. <year>2020</year>;<volume>161</volume>(<issue>9</issue>):<fpage>1976</fpage>&#8211;<lpage>1982</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000001939</pub-id><pub-id pub-id-type="pmid">32694387</pub-id><pub-id pub-id-type="pmcid">PMC7680716</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rikard</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Strahan</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Schmit</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Guy</surname><given-names>GP</given-names></string-name>. <article-title>Chronic pain among adults - United States, 2019-2021</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic></source>. <year>2023</year>;<volume>72</volume>(<issue>15</issue>):<fpage>379</fpage>&#8211;<lpage>385</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm7215a1</pub-id><pub-id pub-id-type="pmid">37053114</pub-id><pub-id pub-id-type="pmcid">PMC10121254</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cohen</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Vase</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hooten</surname><given-names>WM</given-names></string-name>. <article-title>Chronic pain: an update on burden, best practices, and new advances</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2021</year>;<volume>397</volume>(<issue>10289</issue>):<fpage>2082</fpage>&#8211;<lpage>2097</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)00393-7</pub-id><pub-id pub-id-type="pmid">34062143</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Center for drug evaluation and research. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products guidance for industry</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/96643/download" ext-link-type="uri">https://www.fda.gov/media/96643/download</ext-link>. <date-in-citation>Accessed <month>July</month><day>24</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="webpage"><collab>Data Analysis &amp; Resources</collab>. <article-title>US center for disease control and prevention</article-title>; <year>2022</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/opioids/data/analysis-resources.html" ext-link-type="uri">https://www.cdc.gov/opioids/data/analysis-resources.html</ext-link>. <date-in-citation>Accessed <month>July</month><day>24</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="webpage"><collab>Provisional drug overdose death counts</collab>. <article-title>US center for disease control and prevention</article-title>; <year>2023</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link>. <date-in-citation>Accessed <month>July</month><day>24</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="webpage"><article-title>The economic toll of the opioid crisis reached nearly $1.5 trillion in 2020</article-title>. <source>Joint Economic Committee</source>. <comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jec.senate.gov/public/index.cfm/democrats/2022/9/the-economic-toll-of-the-opioid-crisis-reached-nearly-1-5-trillion-in-2020" ext-link-type="uri">https://www.jec.senate.gov/public/index.cfm/democrats/2022/9/the-economic-toll-of-the-opioid-crisis-reached-nearly-1-5-trillion-in-2020</ext-link>. <date-in-citation>Accessed <month>April</month><day>28</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Florence</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>K</given-names></string-name>. <article-title>The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2021</year>;<volume>218</volume>:<fpage>108350</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.108350</pub-id><pub-id pub-id-type="pmid">33121867</pub-id><pub-id pub-id-type="pmcid">PMC8091480</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Webster</surname><given-names>LR</given-names></string-name>. <article-title>Risk factors for opioid-use disorder and overdose</article-title>. <source><italic toggle="yes">Anesth Analg</italic></source>. <year>2017</year>;<volume>125</volume>(<issue>5</issue>):<fpage>1741</fpage>&#8211;<lpage>1748</lpage>. doi:<pub-id pub-id-type="doi">10.1213/ANE.0000000000002496</pub-id><pub-id pub-id-type="pmid">29049118</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="webpage"><string-name name-style="western"><surname>Dydyk</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>M</given-names></string-name><article-title>Opioid use disorder</article-title>. <source>StatPearls Publishing</source>; <year>2023</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK553166/#" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK553166/#</ext-link>. <date-in-citation>Accessed <month>December</month><day>1</day>, 2023</date-in-citation>.<pub-id pub-id-type="pmid">31985959</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Berrettini</surname><given-names>W</given-names></string-name>. <article-title>A brief review of the genetics and pharmacogenetics of opioid use disorders</article-title>. <source><italic toggle="yes">Dialogues Clin Neurosci</italic></source>. <year>2017</year>;<volume>19</volume>(<issue>3</issue>):<fpage>229</fpage>&#8211;<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.31887/DCNS.2017.19.3/wberrettini</pub-id><pub-id pub-id-type="pmid">29302220</pub-id><pub-id pub-id-type="pmcid">PMC5741106</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>CM</given-names></string-name>. <article-title>Opioid addiction, genetic susceptibility, and medical treatments: a review</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2019</year>;<volume>20</volume>(<issue>17</issue>). doi:<pub-id pub-id-type="doi">10.3390/ijms20174294</pub-id><pub-id pub-id-type="pmcid">PMC6747085</pub-id><pub-id pub-id-type="pmid">31480739</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hernandez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>MacKinnon</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Branscum</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Cuadros</surname><given-names>DF</given-names></string-name>. <article-title>&#8221;Know your epidemic, know your response&#8221;: epidemiological assessment of the substance use disorder crisis in the United States</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2021</year>;<volume>16</volume>(<issue>5</issue>):<fpage>e0251502</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0251502</pub-id><pub-id pub-id-type="pmid">34038441</pub-id><pub-id pub-id-type="pmcid">PMC8153501</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McCance-Katz</surname><given-names>EF</given-names></string-name>. <article-title>Co-occurring substance use and mental disorders among adults with opioid use disorder</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2019</year>;<volume>197</volume>:<fpage>78</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.12.030</pub-id><pub-id pub-id-type="pmid">30784952</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Feingold</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brill</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Goor-Aryeh</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Delayahu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lev-Ran</surname><given-names>S</given-names></string-name>. <article-title>The association between severity of depression and prescription opioid misuse among chronic pain patients with and without anxiety: a cross-sectional study</article-title>. <source><italic toggle="yes">J Affect Disord</italic></source>. <year>2018</year>;<volume>235</volume>:<fpage>293</fpage>&#8211;<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jad.2018.04.058</pub-id><pub-id pub-id-type="pmid">29660645</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="webpage"><collab>Institute for Clinical and Economic Review</collab>. <article-title>Draft evidence report&#8212;abuse deterrent formulations of opioids: effectiveness and value</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://icerorg.wpengine.com/wp-content/uploads/2020/10/NECEPAC_ADF_Final_Report_08_08_17.pdf" ext-link-type="uri">http://icerorg.wpengine.com/wp-content/uploads/2020/10/NECEPAC_ADF_Final_Report_08_08_17.pdf</ext-link>. <date-in-citation>Accessed <month>December</month><day>11</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Konakanchi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sethi</surname><given-names>R</given-names></string-name>. <article-title>The growing epidemic of opioid use disorder in the elderly and its treatment: a review of the literature</article-title>. <source><italic toggle="yes">Prim Care Companion CNS Disord</italic></source>. <year>2023</year>;<volume>25</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.4088/PCC.21r03223</pub-id><pub-id pub-id-type="pmid">36638540</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pergolizzi</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>LeQuang</surname><given-names>JA</given-names></string-name>. <article-title>Aging high: opioid use disorder in the elderly population</article-title>. <source><italic toggle="yes">OBM Geriatric</italic></source>. <year>2019</year>;<volume>3</volume>(<issue>2</issue>):<fpage>1</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.21926/obm.geriatr.1902047</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dufort</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Samaan</surname><given-names>Z</given-names></string-name>. <article-title>Problematic opioid use among older adults: epidemiology, adverse outcomes and treatment considerations</article-title>. <source><italic toggle="yes">Drugs Aging</italic></source>. <year>2021</year>;<volume>38</volume>(<issue>12</issue>):<fpage>1043</fpage>&#8211;<lpage>1053</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40266-021-00893-z</pub-id><pub-id pub-id-type="pmid">34490542</pub-id><pub-id pub-id-type="pmcid">PMC8421190</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Eisdorfer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galinkin</surname><given-names>J</given-names></string-name>. <article-title>Opioid use disorder in children and adolescents: risk factors, detection, and treatment</article-title>. <source><italic toggle="yes">Clin J Pain</italic></source>. <year>2019</year>;<volume>35</volume>(<issue>6</issue>):<fpage>521</fpage>&#8211;<lpage>524</lpage>. doi:<pub-id pub-id-type="doi">10.1097/AJP.0000000000000708</pub-id><pub-id pub-id-type="pmid">30985401</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>McCabe</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>West</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Veliz</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>McCabe</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Stoddard</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>CJ</given-names></string-name>. <article-title>Trends in medical and nonmedical use of prescription opioids among US adolescents: 1976&#8211;2015</article-title>. <source><italic toggle="yes">Pediatrics</italic></source>. <year>2017</year>;<volume>139</volume>(<issue>4</issue>). doi:<pub-id pub-id-type="doi">10.1542/peds.2016-2387</pub-id><pub-id pub-id-type="pmcid">PMC5369669</pub-id><pub-id pub-id-type="pmid">28320868</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wilson</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Abebe</surname><given-names>KZ</given-names></string-name>, <string-name name-style="western"><surname>Kraemer</surname><given-names>K</given-names></string-name>, et al. <article-title>Trajectories of opioid use following first opioid prescription in opioid-naive youths and young adults</article-title>. <source><italic toggle="yes">JAMA Network Open</italic></source>. <year>2021</year>;<volume>4</volume>(<issue>4</issue>):<fpage>e214552</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.4552</pub-id><pub-id pub-id-type="pmid">33885777</pub-id><pub-id pub-id-type="pmcid">PMC8063062</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hadland</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bagley</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gai</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Opioid use disorder and overdose among youth following an initial opioid prescription</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2021</year>;<volume>116</volume>(<issue>10</issue>):<fpage>2790</fpage>&#8211;<lpage>2800</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15487</pub-id><pub-id pub-id-type="pmid">33739476</pub-id><pub-id pub-id-type="pmcid">PMC8429061</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Balyan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hahn</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chidambaran</surname><given-names>V</given-names></string-name>. <article-title>Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic</article-title>. <source><italic toggle="yes">Expert Opin Drug Metab Toxicol</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>125</fpage>&#8211;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1080/17425255.2020.1721458</pub-id><pub-id pub-id-type="pmid">31976778</pub-id><pub-id pub-id-type="pmcid">PMC7199505</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brennan</surname><given-names>MJ</given-names></string-name>. <article-title>Update on prescription extended-release opioids and appropriate patient selection</article-title>. <source><italic toggle="yes">J Multidiscip Healthc</italic></source>. <year>2013</year>;<volume>6</volume>:<fpage>265</fpage>&#8211;<lpage>280</lpage>. doi:<pub-id pub-id-type="doi">10.2147/JMDH.S38562</pub-id><pub-id pub-id-type="pmid">23900563</pub-id><pub-id pub-id-type="pmcid">PMC3726523</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gudin</surname><given-names>J</given-names></string-name>. <article-title>Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza((R)) ER (oxycodone DETERx((R)) formulation): a review of published studies</article-title>. <source><italic toggle="yes">J Opioid Manag</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>127</fpage>&#8211;<lpage>139</lpage>. doi:<pub-id pub-id-type="doi">10.5055/jom.2020.0559</pub-id><pub-id pub-id-type="pmid">32329888</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="book"><article-title>XTAMPZA<sup>&#174;</sup> ER (oxycodone) extended-release capsules [package insert]</article-title>. <publisher-name>Collegium Pharmaceutical, Inc</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="book"><article-title>MS CONTIN<sup>&#174;</sup> (morphine sulfate extended-release tablets), for oral use, CII. [package insert]</article-title>. <publisher-loc>Purdue Pharma, LP</publisher-loc>; <year>2021</year>.</mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="book"><article-title>OXYCONTIN<sup>&#174;</sup> (oxycodone hydrochloride) extended-release tablets, for oral use, CII. [package insert]</article-title>. <publisher-loc>Purdue Pharma, LP</publisher-loc>; <year>2021</year>.</mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>HM</given-names></string-name>. <article-title>Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a Phase 3, randomized, double-blind, multicenter study</article-title>. <source><italic toggle="yes">J Pain</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>8</issue>):<fpage>835</fpage>&#8211;<lpage>844</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpain.2014.04.008</pub-id><pub-id pub-id-type="pmid">24846822</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Taber</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lynch</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ripa</surname><given-names>SR</given-names></string-name>. <article-title>Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain</article-title>. <source><italic toggle="yes">Postgrad Med</italic></source>. <year>2016</year>;<volume>128</volume>(<issue>1</issue>):<fpage>23</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00325481.2016.1134022</pub-id><pub-id pub-id-type="pmid">26681111</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Peniston</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Gould</surname><given-names>E</given-names></string-name>. <article-title>Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use</article-title>. <source><italic toggle="yes">Clin Ther</italic></source>. <year>2009</year>;<volume>31</volume>(<issue>2</issue>):<fpage>347</fpage>&#8211;<lpage>359</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinthera.2009.02.019</pub-id><pub-id pub-id-type="pmid">19302907</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nalamachu</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Kutch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hale</surname><given-names>ME</given-names></string-name>. <article-title>Safety and tolerability of once-daily OROS((R)) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies</article-title>. <source><italic toggle="yes">J Pain Symptom Manage</italic></source>. <year>2012</year>;<volume>44</volume>(<issue>6</issue>):<fpage>852</fpage>&#8211;<lpage>865</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpainsymman.2011.12.280</pub-id><pub-id pub-id-type="pmid">22795050</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Iwanicki</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Severtson</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>McDaniel</surname><given-names>H</given-names></string-name>, et al. <article-title>Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2016</year>;<volume>11</volume>(<issue>12</issue>):<fpage>e0167499</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0167499</pub-id><pub-id pub-id-type="pmid">27936038</pub-id><pub-id pub-id-type="pmcid">PMC5147916</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Webster</surname><given-names>LR</given-names></string-name>. <article-title>Eight principles for safer opioid prescribing</article-title>. <source><italic toggle="yes">Pain Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>7</issue>):<fpage>959</fpage>&#8211;<lpage>961</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pme.12194</pub-id><pub-id pub-id-type="pmid">23841682</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Webster</surname><given-names>LR</given-names></string-name>. <part-title>The prescription drug abuse epidemic and emerging prescribing guidelines</part-title>. In<source><italic toggle="yes">Essentials of Pain Medicine</italic></source>; <year>2018</year>:<fpage>389</fpage>&#8211;<lpage>394.e1</lpage></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="webpage"><collab>Veterans Affairs &amp; Department of Defense</collab>. <article-title>VA/DoD Clinical practice guideline for opioid therapy for pain</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf" ext-link-type="uri">https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf</ext-link>. <date-in-citation>Accessed <month>July</month><day>24</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="book"><collab>National Academies of Sciences</collab>. <source><italic toggle="yes">Engineering, and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use</italic></source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>The National Academies Press</publisher-name>; <year>2017</year>.<pub-id pub-id-type="pmid">29023083</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gasior</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bond</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Malamut</surname><given-names>R</given-names></string-name>. <article-title>Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations</article-title>. <source><italic toggle="yes">Postgrad Med</italic></source>. <year>2016</year>;<volume>128</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>96</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00325481.2016.1120642</pub-id><pub-id pub-id-type="pmid">26566680</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Harris</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Perrino</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>I</given-names></string-name>, et al. <article-title>Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users</article-title>. <source><italic toggle="yes">J Clin Pharmacol</italic></source>. <year>2014</year>;<volume>54</volume>(<issue>4</issue>):<fpage>468</fpage>&#8211;<lpage>477</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcph.235</pub-id><pub-id pub-id-type="pmid">24243216</pub-id><pub-id pub-id-type="pmcid">PMC4263153</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Park</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Otte</surname><given-names>A</given-names></string-name>. <article-title>Prevention of opioid abuse and treatment of opioid addiction: current status and future possibilities</article-title>. <source><italic toggle="yes">Annu Rev Biomed Eng</italic></source>. <year>2019</year>;<volume>21</volume>:<fpage>61</fpage>&#8211;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-bioeng-060418-052155</pub-id><pub-id pub-id-type="pmid">30786212</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Carinci</surname><given-names>AJ</given-names></string-name>. <article-title>Abuse-deterrent opioid analgesics: a guide for clinicians</article-title>. <source><italic toggle="yes">Pain Manag</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.2217/pmt-2019-0052</pub-id><pub-id pub-id-type="pmid">31916895</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Abuse-deterrent opioid analgesics</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics" ext-link-type="uri">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics</ext-link>. <date-in-citation>Accessed <month>May</month><day>8</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nguyen</surname><given-names>T</given-names></string-name>. <article-title>Abuse-deterrent opioids: worth the cost and effort?</article-title><source><italic toggle="yes">Chem. Eng. News</italic></source>. <year>2017</year>;<volume>95</volume>(<issue>45</issue>):<fpage>34</fpage>&#8211;<lpage>36</lpage>.</mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="webpage"><collab>University of Massachusetts Medical School</collab>. <article-title>Drug formulary commission monograph: oxycodone extended-release (OxyContin<sup>&#174;</sup>)</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mass.gov/doc/oxycontin-drug-monograph-amended/download" ext-link-type="uri">https://www.mass.gov/doc/oxycontin-drug-monograph-amended/download</ext-link>. <date-in-citation>Accessed <month>July</month><day>24</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Harris</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Cipriano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Colucci</surname><given-names>SV</given-names></string-name>, et al. <article-title>Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users</article-title>. <source><italic toggle="yes">Pain Med</italic></source>. <year>2017</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1278</fpage>&#8211;<lpage>1291</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnw208</pub-id><pub-id pub-id-type="pmid">27651514</pub-id><pub-id pub-id-type="pmcid">PMC5914330</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="webpage"><collab>FDA advisory committee briefing document</collab>. <article-title>RoxyBond (TM) (oxycodone hydrochloride) immediate-release tablets</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/104339/download" ext-link-type="uri">https://www.fda.gov/media/104339/download</ext-link>. <date-in-citation>Accessed <month>July</month><day>24</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fleming</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Scungio</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Grima</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Mayock</surname><given-names>SP</given-names></string-name>. <article-title>In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx(R) microspheres</article-title>. <source><italic toggle="yes">J Opioid Manag</italic></source>. <year>2016</year>;<volume>12</volume>(<issue>1</issue>):<fpage>57</fpage>&#8211;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.5055/jom.2016.0312</pub-id><pub-id pub-id-type="pmid">26908304</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Adler</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Mallick-Searle</surname><given-names>T</given-names></string-name>. <article-title>An overview of abuse-deterrent opioids and recommendations for practical patient care</article-title>. <source><italic toggle="yes">J Multidiscip Healthc</italic></source>. <year>2018</year>;<volume>11</volume>:<fpage>323</fpage>&#8211;<lpage>332</lpage>. doi:<pub-id pub-id-type="doi">10.2147/JMDH.S166915</pub-id><pub-id pub-id-type="pmid">30026658</pub-id><pub-id pub-id-type="pmcid">PMC6045950</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hirsch</surname><given-names>R</given-names></string-name>. <article-title>The opioid epidemic: it&#8217;s time to place blame where it belongs</article-title>. <source><italic toggle="yes">Mo Med</italic></source>. <year>2017</year>;<volume>114</volume>(<issue>2</issue>):<fpage>82</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">30228543</pub-id><pub-id pub-id-type="pmcid">PMC6140023</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Timeline of selected FDA activities and significant events addressing substance use and overdose prevention</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose" ext-link-type="uri">https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose</ext-link>. <date-in-citation>Accessed <month>August</month><day>4</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cone</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Giordano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weingarten</surname><given-names>B</given-names></string-name>. <article-title>An iterative model for in vitro laboratory assessment of tamper deterrent formulations</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2013</year>;<volume>131</volume>(<issue>1&#8211;2</issue>):<fpage>100</fpage>&#8211;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2012.12.006</pub-id><pub-id pub-id-type="pmid">23332441</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gudin</surname><given-names>J</given-names></string-name>. <article-title>Oxycodone DETERx(<sup>&#174;</sup>): a novel abuse-deterrent, extended-release analgesic option for the treatment of patients with chronic pain</article-title>. <source><italic toggle="yes">Pain Ther</italic></source>. <year>2016</year>;<volume>5</volume>(<issue>2</issue>):<fpage>171</fpage>&#8211;<lpage>186</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40122-016-0062-1</pub-id><pub-id pub-id-type="pmid">27873179</pub-id><pub-id pub-id-type="pmcid">PMC5130912</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mayock</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Saim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>AB</given-names></string-name>. <article-title>In vitro drug release after crushing: evaluation of Xtampza((R)) ER and other ER opioid formulations</article-title>. <source><italic toggle="yes">Clin Drug Investig</italic></source>. <year>2017</year>;<volume>37</volume>(<issue>12</issue>):<fpage>1117</fpage>&#8211;<lpage>1124</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40261-017-0561-9</pub-id><pub-id pub-id-type="pmcid">PMC5684282</pub-id><pub-id pub-id-type="pmid">28940174</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Meske</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kopecky</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Passik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shram</surname><given-names>MJ</given-names></string-name>. <article-title>Evaluation of the oral human abuse potential of oxycodone DETERx<sup>&#174;</sup> formulation (Xtampza<sup>&#174;</sup> ER)</article-title>. <source><italic toggle="yes">J Opioid Manag</italic></source>. <year>2018</year>;<volume>14</volume>(<issue>5</issue>):<fpage>359</fpage>&#8211;<lpage>372</lpage>. doi:<pub-id pub-id-type="doi">10.5055/jom.2018.0468</pub-id><pub-id pub-id-type="pmid">30387859</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brennan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Kopecky</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Marseilles</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>AB</given-names></string-name>. <article-title>The comparative pharmacokinetics of physical manipulation by crushing of Xtampza(<sup>&#174;</sup>) ER compared with OxyContin(<sup>&#174;</sup>)</article-title>. <source><italic toggle="yes">Pain Manag</italic></source>. <year>2017</year>;<volume>7</volume>(<issue>6</issue>):<fpage>461</fpage>&#8211;<lpage>472</lpage>. doi:<pub-id pub-id-type="doi">10.2217/pmt-2017-0030</pub-id><pub-id pub-id-type="pmid">29171358</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cicero</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>MS</given-names></string-name>. <article-title>Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxyContin</article-title>. <source><italic toggle="yes">JAMA Psychiatry</italic></source>. <year>2015</year>;<volume>72</volume>(<issue>5</issue>):<fpage>424</fpage>&#8211;<lpage>430</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.3043</pub-id><pub-id pub-id-type="pmid">25760692</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Butler</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>AB</given-names></string-name>. <article-title>Relative abuse of crush-resistant prescription opioid tablets via alternative oral modes of administration</article-title>. <source><italic toggle="yes">Pain Med</italic></source>. <year>2018</year>;<volume>19</volume>(<issue>8</issue>):<fpage>1613</fpage>&#8211;<lpage>1627</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnx151</pub-id><pub-id pub-id-type="pmid">29016905</pub-id><pub-id pub-id-type="pmcid">PMC6084581</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Green</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Dailey-Govoni</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>SF</given-names></string-name>. <article-title>Nonmedical use of Xtampza<sup>&#174;</sup> ER and other oxycodone medications in adults evaluated for substance abuse treatment: real-world data from the addiction severity index-multimedia version (ASI-MV<sup>&#174;</sup>)</article-title>. <source><italic toggle="yes">J Pain Res</italic></source>. <year>2021</year>;<volume>14</volume>:<fpage>1773</fpage>&#8211;<lpage>1783</lpage>. doi:<pub-id pub-id-type="doi">10.2147/JPR.S304805</pub-id><pub-id pub-id-type="pmid">34163234</pub-id><pub-id pub-id-type="pmcid">PMC8214548</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Severtson</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Kreider</surname><given-names>SED</given-names></string-name>, <string-name name-style="western"><surname>Amioka</surname><given-names>ECMZ</given-names></string-name>, <string-name name-style="western"><surname>Iwanicki</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Rc.</surname><given-names>D</given-names></string-name>. <article-title>Postmarketing analysis of misuse, abuse, and diversion of Xtampza ER</article-title>. <source><italic toggle="yes">Pain Med</italic></source>. <year>2020</year>;<volume>21</volume>(<issue>12</issue>):<fpage>3660</fpage>&#8211;<lpage>3668</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnaa272</pub-id><pub-id pub-id-type="pmid">33094329</pub-id><pub-id pub-id-type="pmcid">PMC7770232</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jewell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Olsen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Iwanicki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dart</surname><given-names>R</given-names></string-name>. <article-title>A cross-sectional study of tampering in Xtampza ER, an abuse-deterrent formulation of an extended-release opioid, in a treatment center population</article-title>. <source><italic toggle="yes">Clin Drug Investig</italic></source>. <year>2023</year>;<volume>43</volume>(<issue>3</issue>):<fpage>197</fpage>&#8211;<lpage>203</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40261-023-01248-9</pub-id><pub-id pub-id-type="pmcid">PMC10049928</pub-id><pub-id pub-id-type="pmid">36859697</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Green</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Bucher Bartelson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Le Lait</surname><given-names>MC</given-names></string-name>, et al. <article-title>Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2017</year>;<volume>175</volume>:<fpage>140</fpage>&#8211;<lpage>145</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.01.039</pub-id><pub-id pub-id-type="pmid">28414990</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Butler</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Cassidy</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Chilcoat</surname><given-names>H</given-names></string-name>, et al. <article-title>Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment</article-title>. <source><italic toggle="yes">J Pain</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>4</issue>):<fpage>351</fpage>&#8211;<lpage>358</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpain.2012.08.008</pub-id><pub-id pub-id-type="pmid">23127293</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gudin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Levy-Cooperman</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kopecky</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>AB</given-names></string-name>. <article-title>Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties</article-title>. <source><italic toggle="yes">Pain Med</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>11</issue>):<fpage>2142</fpage>&#8211;<lpage>2151</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pme.12834</pub-id><pub-id pub-id-type="pmid">26108255</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kopecky</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Levy-Cooperman</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>MS</surname><given-names>E</given-names></string-name>. <article-title>Oral human abuse potential of oxycodone DETERx(<sup>&#174;</sup>) (Xtampza(<sup>&#174;</sup>) ER)</article-title>. <source><italic toggle="yes">J Clin Pharmacol</italic></source>. <year>2017</year>;<volume>57</volume>(<issue>4</issue>):<fpage>500</fpage>&#8211;<lpage>512</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcph.833</pub-id><pub-id pub-id-type="pmid">27669664</pub-id><pub-id pub-id-type="pmcid">PMC5363337</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chilcoat</surname><given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Coplan</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Harikrishnan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>L</given-names></string-name>. <article-title>Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2016</year>;<volume>165</volume>:<fpage>221</fpage>&#8211;<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.06.009</pub-id><pub-id pub-id-type="pmid">27372220</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Coplan</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Chilcoat</surname><given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>SF</given-names></string-name>, et al. <article-title>The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting</article-title>. <source><italic toggle="yes">Clin Pharmacol Ther</italic></source>. <year>2016</year>;<volume>100</volume>(<issue>3</issue>):<fpage>275</fpage>&#8211;<lpage>286</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cpt.390</pub-id><pub-id pub-id-type="pmid">27170195</pub-id><pub-id pub-id-type="pmcid">PMC5102571</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hwang</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name>. <article-title>Impact of abuse-deterrent OxyContin on prescription opioid utilization</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2015</year>;<volume>24</volume>(<issue>2</issue>):<fpage>197</fpage>&#8211;<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.3723</pub-id><pub-id pub-id-type="pmid">25393216</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Khouja</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tadrous</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matusiak</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Suda</surname><given-names>K</given-names></string-name>. <article-title>Opioid prescribing in United States health systems, 2015 to 2019</article-title>. <source><italic toggle="yes">Value Health</italic></source>. <year>2021</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1279</fpage>&#8211;<lpage>1284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jval.2021.04.1274</pub-id><pub-id pub-id-type="pmid">34452707</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>. <article-title>Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016&#8211;2021</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2023</year>;<volume>248</volume>:<fpage>109933</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2023.109933</pub-id><pub-id pub-id-type="pmid">37267746</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Schieber</surname><given-names>LZ</given-names></string-name>, <string-name name-style="western"><surname>Guy</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name>, et al. <article-title>Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006&#8211;2017</article-title>. <source><italic toggle="yes">JAMA Network Open</italic></source>. <year>2019</year>;<volume>2</volume>(<issue>3</issue>):<fpage>e190665</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.0665</pub-id><pub-id pub-id-type="pmid">30874783</pub-id><pub-id pub-id-type="pmcid">PMC6484643</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sahebi-Fakhrabad</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sadeghi</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Handfield</surname><given-names>R</given-names></string-name>. <article-title>Evaluating state-level prescription drug monitoring program (PDMP) and pill mill effects on opioid consumption in pharmaceutical supply chain</article-title>. <source><italic toggle="yes">Healthcare</italic></source>. <year>2023</year>;<volume>11</volume>(<issue>3</issue>). doi:<pub-id pub-id-type="doi">10.3390/healthcare11030437</pub-id><pub-id pub-id-type="pmcid">PMC9914561</pub-id><pub-id pub-id-type="pmid">36767012</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gray</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Vandergrift</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lipner</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name>. <article-title>Clinical knowledge and trends in physicians&#8217; prescribing of opioids for new onset back pain, 2009&#8211;2017</article-title>. <source><italic toggle="yes">JAMA Network Open</italic></source>. <year>2021</year>;<volume>4</volume>(<issue>7</issue>):<fpage>e2115328</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.15328</pub-id><pub-id pub-id-type="pmid">34196714</pub-id><pub-id pub-id-type="pmcid">PMC8251502</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Dasgupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Nocera</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lazard</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Slavova</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>PR</given-names></string-name>. <article-title>Abuse-deterrent opioids: a survey of physician beliefs, behaviors, and psychology</article-title>. <source><italic toggle="yes">Pain Ther</italic></source>. <year>2022</year>;<volume>11</volume>(<issue>1</issue>):<fpage>133</fpage>&#8211;<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40122-021-00343-z</pub-id><pub-id pub-id-type="pmid">34870790</pub-id><pub-id pub-id-type="pmcid">PMC8861217</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Opioid analgesic risk evaluation and mitigation strategy(REMS)</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems" ext-link-type="uri">https://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems</ext-link>. <date-in-citation>Accessed <month>July</month><day>7</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Brooks</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kominek</surname><given-names>C</given-names></string-name>. <article-title>ADF: abuse-deterrent formulation or another disillusioned formulation?</article-title><source><italic toggle="yes">Pain Med</italic></source>. <year>2018</year>;<volume>19</volume>(<issue>5</issue>):<fpage>907</fpage>&#8211;<lpage>909</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pm/pnx232</pub-id><pub-id pub-id-type="pmid">29025056</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Petrilla</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Marrett</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kwong</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Pezalla</surname><given-names>E</given-names></string-name>. <article-title>Association between formulary coverage and use of abuse-deterrent prescription opioids, risk for abuse or overdose, and associated healthcare resource utilization</article-title>. <source><italic toggle="yes">Am Health Drug Benefits</italic></source>. <year>2020</year>;<volume>13</volume>(<issue>1</issue>):<fpage>21</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32165996</pub-id><pub-id pub-id-type="pmcid">PMC7040955</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kumar</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Agboola</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Synnott</surname><given-names>PG</given-names></string-name>, et al. <article-title>Impact of abuse deterrent formulations of opioids in patients with chronic pain in the United States: a cost-effectiveness model</article-title>. <source><italic toggle="yes">Value Health</italic></source>. <year>2019</year>;<volume>22</volume>(<issue>4</issue>):<fpage>416</fpage>&#8211;<lpage>422</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jval.2018.12.005</pub-id><pub-id pub-id-type="pmid">30975392</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gill</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nafees</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Poole</surname><given-names>R</given-names></string-name>. <article-title>A qualitative interview study of GPs&#8217; experiences of prescribing opioid medication for chronic pain</article-title>. <source><italic toggle="yes">BJGP Open</italic></source>. <year>2022</year>;<volume>6</volume>(<issue>4</issue>). doi:<pub-id pub-id-type="doi">10.3399/BJGPO.2022.0085</pub-id><pub-id pub-id-type="pmcid">PMC9904793</pub-id><pub-id pub-id-type="pmid">36216370</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Litman</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Pagan</surname><given-names>OH</given-names></string-name>, <string-name name-style="western"><surname>Cicero</surname><given-names>TJ</given-names></string-name>. <article-title>Abuse-deterrent opioid formulations</article-title>. <source><italic toggle="yes">Anesthesiology</italic></source>. <year>2018</year>;<volume>128</volume>(<issue>5</issue>):<fpage>1015</fpage>&#8211;<lpage>1026</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ALN.0000000000002031</pub-id><pub-id pub-id-type="pmid">29252508</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Olatoke</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Zah</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Stanicic</surname><given-names>F</given-names></string-name>, et al. <article-title>A US retrospective claims analysis comparing healthcare costs of patients transitioning from immediate-release oxycodone to two different formulations of extended-release oxycodone: xtampza ER or OxyContin</article-title>. <source><italic toggle="yes">Clinicoecon Outcomes Res</italic></source>. <year>2022</year>;<volume>14</volume>:<fpage>119</fpage>&#8211;<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.2147/CEOR.S340290</pub-id><pub-id pub-id-type="pmid">35264862</pub-id><pub-id pub-id-type="pmcid">PMC8901186</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="webpage"><collab>Ballotpedia</collab>. <article-title>Opioid prescription limits and policies by state</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ballotpedia.org/Opioid_prescription_limits_and_policies_by_state" ext-link-type="uri">https://ballotpedia.org/Opioid_prescription_limits_and_policies_by_state</ext-link>. <date-in-citation>Accessed <month>July</month><day>7</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Passik</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Heit</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>DeGeorge</surname><given-names>M</given-names></string-name>. <article-title>Reality and responsibility revisited: stakeholder accountability in the effort to develop safer opioids</article-title>. <source><italic toggle="yes">J Opioid Manag</italic></source>. <year>2017</year>;<volume>13</volume>(<issue>6</issue>):<fpage>391</fpage>&#8211;<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.5055/jom.2017.0405</pub-id><pub-id pub-id-type="pmid">29308586</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="webpage"><collab>US Center for Disease Control and Prevention</collab>. <article-title>US opioid dispensing rate maps</article-title>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/drugoverdose/rxrate-maps/index.html" ext-link-type="uri">https://www.cdc.gov/drugoverdose/rxrate-maps/index.html</ext-link>.<date-in-citation>Accessed <month>April</month><day>28</day>, 2023</date-in-citation>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>